<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-19004" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Cataplexy</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Mirabile</surname>
            <given-names>Vincent S.</given-names>
          </name>
          <aff>Jefferson Washington Township Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sharma</surname>
            <given-names>Sandeep</given-names>
          </name>
          <aff>Mery Fitzgerald Hospital</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Vincent Mirabile declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sandeep Sharma declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>12</day>
          <month>6</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-19004.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Cataplexy, a physical feature of narcolepsy, is characterized by transient episodes of voluntary muscle weakness precipitated by intense emotion. Subjective descriptions of cataplexy can assist in the identification of narcolepsy, as this feature is almost unique to the disorder. While one-third of patients present with the classic narcolepsy tetrad (cataplexy, excessive daytime sleepiness, hypnagogic hallucinations, and sleep paralysis), two-thirds of patients with narcolepsy patients are affected by cataplexy. This activity reviews the role of the interprofessional healthcare team in improving care for patients with narcolepsy, by raising awareness of cataplexy.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Review the etiology of cataplexy.</p></list-item><list-item><p>Summarize the evaluation of cataplexy.</p></list-item><list-item><p>Outline the treatment and management options available for cataplexy.</p></list-item><list-item><p>Review the importance of improving care coordination among interprofessional team members to improve outcomes for patients affected by cataplexy.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=19004&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=19004">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-19004.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Cataplexy, a physical feature of narcolepsy, is characterized by transient episodes of voluntary muscle weakness precipitated by intense emotion.<xref ref-type="bibr" rid="article-19004.r1">[1]</xref>&#x000a0;Subjective descriptions of cataplexy can assist in the identification of narcolepsy, as this feature is all but unique to the disorder.<xref ref-type="bibr" rid="article-19004.r2">[2]</xref>&#x000a0;Unfortunately, cataplexy is challenging to identify, often going undetected. While 19% of patients diagnosed with narcolepsy also get diagnosed with cataplexy, estimates are that roughly 70% of patients with narcolepsy also have cataplexy.<xref ref-type="bibr" rid="article-19004.r3">[3]</xref></p>
      </sec>
      <sec id="article-19004.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Type 1 narcolepsy (historically known as narcolepsy with cataplexy) is due to a deficiency of orexin-A, a wakefulness-promoting peptide neurotransmitter.<xref ref-type="bibr" rid="article-19004.r1">[1]</xref>&#x000a0;There is a near-perfect association of type 1 narcolepsy with HLA-DQB1*06:02,&#x000a0;leading to the auto-immune hypothesis, which posits&#x000a0;a selective, self-destruction of orexin-A producing neurons as the driving force behind the disorder.<xref ref-type="bibr" rid="article-19004.r4">[4]</xref><xref ref-type="bibr" rid="article-19004.r5">[5]</xref>&#x000a0;The onset of narcolepsy is seasonal, most often surfacing in the spring, following upper respiratory tract infections that had occurred in the preceding months.<xref ref-type="bibr" rid="article-19004.r6">[6]</xref>&#x000a0;Moreover, there was an increased incidence of narcolepsy following the use of the 2009 European Pandemrix vaccination, suggesting the involvement of molecular mimicry in the development of this disorder.<xref ref-type="bibr" rid="article-19004.r7">[7]</xref></p>
        <p>Secondary narcolepsy, on the other hand, is due to the development of lateral hypothalamic lesions. Although rare, lesions secondary to arteriovenous malformations, cerebrovascular accidents, inflammatory processes, and neoplasms result in the destruction of orexin-A-producing neurons.<xref ref-type="bibr" rid="article-19004.r8">[8]</xref><xref ref-type="bibr" rid="article-19004.r9">[9]</xref>&#x000a0;It is worth noting that other neurological deficits are often evident in individuals who develop secondary narcolepsy, as lesions are not typically confined to the lateral hypothalamus.</p>
      </sec>
      <sec id="article-19004.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>In the U.S., narcolepsy affects 1 in 2000 individuals with an equal distribution amongst the sexes.<xref ref-type="bibr" rid="article-19004.r1">[1]</xref>&#x000a0;Symptom onset most frequently occurs during adolescence; however, diagnosis often gets delayed on average by 15 years.<xref ref-type="bibr" rid="article-19004.r10">[10]</xref>&#x000a0;Two forms of narcolepsy exist: type 1 is associated with cataplexy while this feature is absent in type 2. In the U.S., Type 1 narcolepsy affects 1&#x000a0;to 2 in 4000 individuals.<xref ref-type="bibr" rid="article-19004.r11">[11]</xref></p>
      </sec>
      <sec id="article-19004.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>In addition to the physical feature of cataplexy, type 1 narcolepsy further distinguishes from type 2 narcolepsy on the molecular level. In patients with type 1 narcolepsy, the examination of cerebrospinal fluid demonstrates decreased levels of orexin-A, a wakefulness-promoting peptide neurotransmitter.<xref ref-type="bibr" rid="article-19004.r1">[1]</xref>&#x000a0;Neurons located in the lateral hypothalamus produce orexin-A; it potentiates the production of the following neurotransmitters: dopamine, histamine, norepinephrine, and serotonin, leading to the suppression of rapid eye movement (REM) sleep.<xref ref-type="bibr" rid="article-19004.r12">[12]</xref>&#x000a0;Intense emotions transmitted from the medial prefrontal cortex to the amygdala, in conjunction with the loss of orexin-A, decrease inhibitory signals of REM sleep, ultimately inhibiting motor neurons in the pons, leading to muscle paralysis and cataplexy.<xref ref-type="bibr" rid="article-19004.r1">[1]</xref></p>
      </sec>
      <sec id="article-19004.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Obtaining an accurate and detailed history is imperative in the diagnosis of narcolepsy. The clinician should perform an investigation of behavioral (i.e., caffeine use, insufficient sleep, poor sleep hygiene, tobacco use, etc.) and alternative diagnoses (i.e., anemia, hypothyroidism, obstructive sleep apnea, etc.) of excessive daytime sleepiness. It is essential to realize that patients with narcolepsy are well-rested following a brief nap or sufficient nights' sleep; however, the symptoms of excessive daytime sleepiness occur within hours of awakening.<xref ref-type="bibr" rid="article-19004.r1">[1]</xref>&#x000a0;In addition to excessive daytime sleepiness, patients with type 1 narcolepsy experience symptoms of disordered regulation of REM sleep (i.e., cataplexy, hypnagogic hallucinations, and sleep paralysis).</p>
        <p>The sudden onset of muscle weakness characterizes cataplexy.<xref ref-type="bibr" rid="article-19004.r1">[1]</xref>&#x000a0;Such episodes are transient, lasting seconds to minutes, and get precipitated by intense emotions.<xref ref-type="bibr" rid="article-19004.r1">[1]</xref>&#x000a0;Cataplectic attacks are more frequently incited by positive emotions (i.e., laughter, excitement, etc.) than negative emotions (i.e., anger, fear, frustration, etc.), with laughter being the most common precipitant.<xref ref-type="bibr" rid="article-19004.r13">[13]</xref>&#x000a0;It is the complete or partial paralysis of voluntary muscles that is responsible for the weakness associated with cataplexy; however, it bears noting that the muscles of eye movement and respiration get spared during these attacks.<xref ref-type="bibr" rid="article-19004.r1">[1]</xref>&#x000a0;The suppression of serotonergic and noradrenergic neuronal circuits permits the complete or partial paralysis of voluntary muscles.<xref ref-type="bibr" rid="article-19004.r14">[14]</xref>&#x000a0;Consciousness, however, is uncompromised during cataplectic attacks as wake-promoting histaminergic signaling is preserved.<xref ref-type="bibr" rid="article-19004.r14">[14]</xref>&#x000a0;Cataplectic attacks typically follow a crescendo pattern, first involving the muscles of the face and neck with progression to the muscles of the trunk and limbs.<xref ref-type="bibr" rid="article-19004.r1">[1]</xref>&#x000a0;Physical findings depend on the severity of each episode, ranging from facial drooping and slurring of speech (partial attacks) to collapse (complete attacks).<xref ref-type="bibr" rid="article-19004.r13">[13]</xref><xref ref-type="bibr" rid="article-19004.r15">[15]</xref>&#x000a0;Episodes of cataplexy often resolve within two minutes, and those afflicted are without lingering effects.</p>
      </sec>
      <sec id="article-19004.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>The diagnosis of type 1 narcolepsy requires the subjective complaint of excessive daytime sleepiness (occurring daily for a minimum of 3 months) in addition to either decreased cerebrospinal fluid (CSF) concentrations of orexin-A or cataplexy in conjunction with the following findings on a multiple sleep latency testing: Mean sleep latency less than or equal to 8 minutes and greater than or equal to 2 sleep-onset REM sleep periods.<xref ref-type="bibr" rid="article-19004.r16">[16]</xref></p>
      </sec>
      <sec id="article-19004.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>While behavior modifications (i.e., planned naps, a sufficient night's sleep) play a role in the management of the excessive daytime sleepiness associated with type 1 narcolepsy, treatment of cataplexy is purely pharmacological. The duration of therapy is indefinite, as type 1 narcolepsy is incurable. It bears mentioning that treatment options include various combinations of medications, often creating an individualized treatment. Clinicians can use the Epworth Sleepiness Scale to follow the response to treatment. For completeness, the pharmacologic treatment of type 1 narcolepsy, as a whole, is presented below:</p>
        <p>Successful management of excessive daytime sleepiness often requires the use of wakefulness-promoting agents, as behavioral modifications fail to provide complete relief.<xref ref-type="bibr" rid="article-19004.r14">[14]</xref>&#x000a0;Modafinil (100 to 400 mg by mouth once daily every morning) and its isolated R-enantiomer, armodafinil (150 to 250 mg by mouth once daily every morning), are considered first-line pharmacologic agents in the management of excessive daytimes sleepiness. While the mechanism of action of these agents is not entirely understood, the thinking is that their effects are due to an increase in dopaminergic signaling via the inhibition of dopamine reuptake.<xref ref-type="bibr" rid="article-19004.r17">[17]</xref>&#x000a0;Two medications received FDA approval in 2019: pitolisant and solriamfetol. Pitolisant (8.9 to 35.6 mg by mouth once daily every morning) is a histamine-3 receptor inverse agonist, while solriamfetol (75 to 300 mg by mouth once daily every morning) is a selective dopamine/norepinephrine reuptake inhibitor.<xref ref-type="bibr" rid="article-19004.r18">[18]</xref>&#x000a0;For breakthrough excessive daytime sleepiness, the following agents are options on an as-needed basis: dextroamphetamine-amphetamine (5 to 60 mg by mouth daily in one to three divided doses) and methylphenidate (5 to 60 mg by mouth daily in two to three divided doses).<xref ref-type="bibr" rid="article-19004.r19">[19]</xref></p>
        <p>Successful management of cataplexy requires the use of REM sleep-suppressing drugs. Such agents increase the concentration of norepinephrine and serotonin. The following pharmacologic agents are considered first-line in the management of cataplexy: Selective serotonin reuptake inhibitors (fluoxetine 10 to 80 mg by mouth daily every morning), norepinephrine reuptake inhibitors (atomoxetine 40 to 80 mg by mouth daily every morning), serotonin/norepinephrine reuptake inhibitors (venlafaxine extended-release 37.5 to 150 mg by mouth once daily every morning), and tricyclic antidepressants (clomipramine 10 to 150 mg by mouth daily every morning). Prescribers of the medications, as mentioned earlier, should keep in mind the following considerations:</p>
        <list list-type="bullet">
          <list-item>
            <p>Tricyclic antidepressants (TCAs) have fallen out of favor for the treatment of cataplexy due to their anticholinergic side effects (i.e., delirium, dry mucous membranes, hyperthermia, ileus, mydriasis, tachycardia, and urinary retention). Moreover, TCA overdose can result in a toxidrome: anticholinergic symptoms, cardiac toxicity, and CNS toxicity. Cardiac toxicity includes interventricular conduction delay (QRS prolongation), right-axis deviation, and tachycardia (anticholinergic effect).<xref ref-type="bibr" rid="article-19004.r20">[20]</xref></p>
          </list-item>
          <list-item>
            <p>Serotonin syndrome is diagnosed clinically using the Hunter criteria: administration of a serotonergic agent in the setting of inducible clonus with either agitation or diaphoresis. It can occur with the use of a single serotonergic agent as prescribed/taken in excess or with the co-ingestion of multiple serotonergic agents simultaneously. Its manifestations are due to an increase of serotonin in the central nervous system. Typical presentation includes altered mental status, increased autonomic activity, and neuromuscular changes. Great care is necessary to avoid the prescription of multiple serotonergic agents in a single patient.<xref ref-type="bibr" rid="article-19004.r21">[21]</xref></p>
          </list-item>
        </list>
        <p>Currently, only one medication has FDA approval for the treatment of both cataplexy and the excessive daytime sleepiness associated with narcolepsy: Sodium oxybate, the sodium salt of gamma-hydroxybutyrate. The mechanism of action of this medication is unknown; however, it is a known metabolite of gamma-aminobutyric acid (GABA). It is therefore thought to work via the GABA-B receptor. This medication is dosed initially at bedtime with subsequent dosing 2.5 to 4 hours later and has a significant salt content of 1100 mg to 1640 mg when dosed in the effective range (6 g to 9 g per night in two divided doses).</p>
        <p>The management of type 1 narcolepsy in children differs slightly from management in adults. In children, the first-line pharmacologic agents for the treatment of symptoms of excessive daytime sleepiness are stimulants such as dextroamphetamine-amphetamine (10 to 40 mg by mouth daily in one to two divided doses) or methylphenidate (10 to 60 mg by mouth daily in two to three divided doses) rather than wakefulness-promoting agents such as armodafinil (50 to 250 mg by mouth once daily every morning) and modafinil (50 to 200 mg by mouth once daily every morning). Moreover, the&#x000a0;first-line pharmacologic agent for the treatment of cataplexy is sodium oxybate (1 to 2 g per night in two divided doses), rather than REM sleep-suppressing drugs, in children over the age of seven. In children under seven with cataplexy requiring treatment, the following REM sleep-suppressing drugs are possible therapies: clomipramine 25 mg by mouth once daily at bedtime, fluoxetine 5 to 10 mg by mouth once daily, or venlafaxine extended-release 25 mg by mouth once daily.</p>
      </sec>
      <sec id="article-19004.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Cataplexy is all but unique to type 1 narcolepsy; therefore, the differential diagnosis of this feature is sparse. Pseudocataplexy, a feature of conversion disorder, is characterized by cataplexy-like attacks; however, the other defining characteristics of narcolepsy are often absent.</p>
        <p>Although rare, cataplexy can occur in the presence of lateral hypothalamic lesions implicated in the development of secondary narcolepsy. Such lesions may arise in the setting of arteriovenous malformations, cerebrovascular accidents, inflammatory processes, and neoplasms.<xref ref-type="bibr" rid="article-19004.r8">[8]</xref><xref ref-type="bibr" rid="article-19004.r9">[9]</xref>&#x000a0;Again, if cataplexy were to occur in such situations, other neurological deficits will likely be evident, as neuronal destruction does not typically remain confined to the hypothalamus.</p>
      </sec>
      <sec id="article-19004.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Patients must be capable self-advocates, accurately describing their symptoms to the clinician, to facilitate the diagnosis of type 1 narcolepsy. While type 1 narcolepsy is an incurable neurological disorder, there are treatment options directed towards symptom management. In patients with narcolepsy with cataplexy, multiple individual pharmacological agents exist for symptomatic management of cataplexy and excessive daytime sleepiness alone, except sodium oxybate, which targets all features of type 1 narcolepsy.</p>
      </sec>
      <sec id="article-19004.s11" sec-type="Complications">
        <title>Complications</title>
        <p>Severe episodes of cataplexy resulting in complete collapse can result in musculoskeletal injury and intracranial hemorrhage.<xref ref-type="bibr" rid="article-19004.r22">[22]</xref>&#x000a0;Factors determining the severity of sequela following a cataplectic fall include age, ground-surface composition, height, preexisting metabolic bone disease, and surrounding objects.</p>
      </sec>
      <sec id="article-19004.s12" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patients with type 1 narcolepsy should be&#x000a0;made aware of the increased risk of sleep-related driving accidents. Alcohol and recreational drugs should be avoided as they may exacerbate symptoms in these patients. Patients and parents should also be educated on the importance of a healthy diet and daily exercise. Patients should be advised to wear a life&#x000a0;jacket when&#x000a0;participating in water-related activities and to only engage in these actions with a partner that is aware of their diagnosis.</p>
      </sec>
      <sec id="article-19004.s13" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Cataplexy, a physical feature of narcolepsy, is characterized by transient episodes of voluntary muscle weakness precipitated by intense emotion.<xref ref-type="bibr" rid="article-19004.r1">[1]</xref>&#x000a0;It is all but unique to type 1 narcolepsy, a disorder due to a deficiency of orexin-A, a wakefulness-promoting peptide neurotransmitter.<xref ref-type="bibr" rid="article-19004.r1">[1]</xref>&#x000a0;Although incurable, multiple individual pharmacological agents exist for symptomatic management of cataplexy and excessive daytime sleepiness. As this disorder is underdiagnosed, it is crucial that patients are active self-advocates and accurately describing their symptoms to health care providers. While the primary care provider is responsible for conducting the preliminary investigation of a patient's symptoms, the diagnosis of type 1 narcolepsy and subsequent management requires an interprofessional team, including the consultation of a board-certified sleep medicine clinician. To ensure improved outcomes, the pharmacist should educate the patient on medication compliance, as well as verifying dosing and checking for interactions to alert the prescriber. Finally, the medications used to treat cataplexy do have serious adverse effects, and a dedicated nurse must closely monitor the patients. Open communication between the interprofessional team members is vital to ensure good outcomes. [Level 5]</p>
      </sec>
      <sec id="article-19004.s14">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=19004&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=19004">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/sleep-disorders/cataplexy/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=19004">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/19004/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=19004">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-19004.s15">
        <title>References</title>
        <ref id="article-19004.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Scammell</surname>
                <given-names>TE</given-names>
              </name>
            </person-group>
            <article-title>Narcolepsy.</article-title>
            <source>N Engl J Med</source>
            <year>2015</year>
            <month>Dec</month>
            <day>31</day>
            <volume>373</volume>
            <issue>27</issue>
            <fpage>2654</fpage>
            <page-range>2654-62</page-range>
            <pub-id pub-id-type="pmid">26716917</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19004.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wren</surname>
                <given-names>BW</given-names>
              </name>
              <name>
                <surname>Clayton</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Mullany</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>Tabaqchali</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Molecular cloning and expression of Clostridium difficile toxin A in Escherichia coli K12.</article-title>
            <source>FEBS Lett</source>
            <year>1987</year>
            <month>Dec</month>
            <day>10</day>
            <volume>225</volume>
            <issue>1-2</issue>
            <fpage>82</fpage>
            <page-range>82-6</page-range>
            <pub-id pub-id-type="pmid">2961615</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19004.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dauvilliers</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Siegel</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Lopez</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Torontali</surname>
                <given-names>ZA</given-names>
              </name>
              <name>
                <surname>Peever</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Cataplexy--clinical aspects, pathophysiology and management strategy.</article-title>
            <source>Nat Rev Neurol</source>
            <year>2014</year>
            <month>Jul</month>
            <volume>10</volume>
            <issue>7</issue>
            <fpage>386</fpage>
            <page-range>386-95</page-range>
            <pub-id pub-id-type="pmid">24890646</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19004.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rogers</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Meehan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Guilleminault</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Grumet</surname>
                <given-names>FC</given-names>
              </name>
              <name>
                <surname>Mignot</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>HLA DR15 (DR2) and DQB1*0602 typing studies in 188 narcoleptic patients with cataplexy.</article-title>
            <source>Neurology</source>
            <year>1997</year>
            <month>Jun</month>
            <volume>48</volume>
            <issue>6</issue>
            <fpage>1550</fpage>
            <page-range>1550-6</page-range>
            <pub-id pub-id-type="pmid">9191765</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19004.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mahlios</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>De la Herr&#x000e1;n-Arita</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Mignot</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>The autoimmune basis of narcolepsy.</article-title>
            <source>Curr Opin Neurobiol</source>
            <year>2013</year>
            <month>Oct</month>
            <volume>23</volume>
            <issue>5</issue>
            <fpage>767</fpage>
            <page-range>767-73</page-range>
            <pub-id pub-id-type="pmid">23725858</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19004.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Han</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Warby</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Faraco</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dong</surname>
                <given-names>SX</given-names>
              </name>
              <name>
                <surname>An</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>QY</given-names>
              </name>
              <name>
                <surname>Yan</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Gao</surname>
                <given-names>ZC</given-names>
              </name>
              <name>
                <surname>Yuan</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Strohl</surname>
                <given-names>KP</given-names>
              </name>
              <name>
                <surname>Mignot</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Narcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in China.</article-title>
            <source>Ann Neurol</source>
            <year>2011</year>
            <month>Sep</month>
            <volume>70</volume>
            <issue>3</issue>
            <fpage>410</fpage>
            <page-range>410-7</page-range>
            <pub-id pub-id-type="pmid">21866560</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19004.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ahmed</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Volkmuth</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Duca</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Corti</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Pallaoro</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pezzicoli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Karle</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rigat</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Rappuoli</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Narasimhan</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Julkunen</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Vuorela</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vaarala</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Nohynek</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Pasini</surname>
                <given-names>FL</given-names>
              </name>
              <name>
                <surname>Montomoli</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Trombetta</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Adams</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Rothbard</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Steinman</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Antibodies to influenza nucleoprotein cross-react with human hypocretin receptor 2.</article-title>
            <source>Sci Transl Med</source>
            <year>2015</year>
            <month>Jul</month>
            <day>01</day>
            <volume>7</volume>
            <issue>294</issue>
            <fpage>294ra105</fpage>
            <pub-id pub-id-type="pmid">26136476</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19004.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aldrich</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Naylor</surname>
                <given-names>MW</given-names>
              </name>
            </person-group>
            <article-title>Narcolepsy associated with lesions of the diencephalon.</article-title>
            <source>Neurology</source>
            <year>1989</year>
            <month>Nov</month>
            <volume>39</volume>
            <issue>11</issue>
            <fpage>1505</fpage>
            <page-range>1505-8</page-range>
            <pub-id pub-id-type="pmid">2812331</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19004.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schwartz</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Stakes</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Hobson</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Transient cataplexy after removal of a craniopharyngioma.</article-title>
            <source>Neurology</source>
            <year>1984</year>
            <month>Oct</month>
            <volume>34</volume>
            <issue>10</issue>
            <fpage>1372</fpage>
            <page-range>1372-5</page-range>
            <pub-id pub-id-type="pmid">6541312</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19004.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thorpy</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Krieger</surname>
                <given-names>AC</given-names>
              </name>
            </person-group>
            <article-title>Delayed diagnosis of narcolepsy: characterization and impact.</article-title>
            <source>Sleep Med</source>
            <year>2014</year>
            <month>May</month>
            <volume>15</volume>
            <issue>5</issue>
            <fpage>502</fpage>
            <page-range>502-7</page-range>
            <pub-id pub-id-type="pmid">24780133</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19004.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Longstreth</surname>
                <given-names>WT</given-names>
              </name>
              <name>
                <surname>Koepsell</surname>
                <given-names>TD</given-names>
              </name>
              <name>
                <surname>Ton</surname>
                <given-names>TG</given-names>
              </name>
              <name>
                <surname>Hendrickson</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>van Belle</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>The epidemiology of narcolepsy.</article-title>
            <source>Sleep</source>
            <year>2007</year>
            <month>Jan</month>
            <volume>30</volume>
            <issue>1</issue>
            <fpage>13</fpage>
            <page-range>13-26</page-range>
            <pub-id pub-id-type="pmid">17310860</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19004.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Feresiadou</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nilsson</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ingelsson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Press</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kmezic</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Nygren</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Svenningsson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Niemel&#x000e4;</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Gordh</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Cunningham</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kultima</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Larsson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Burman</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Measurement of sCD27 in the cerebrospinal fluid identifies patients with neuroinflammatory disease.</article-title>
            <source>J Neuroimmunol</source>
            <year>2019</year>
            <month>Jul</month>
            <day>15</day>
            <volume>332</volume>
            <fpage>31</fpage>
            <page-range>31-36</page-range>
            <pub-id pub-id-type="pmid">30928869</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19004.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Overeem</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>van Nues</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>van der Zande</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>Donjacour</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>van Mierlo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lammers</surname>
                <given-names>GJ</given-names>
              </name>
            </person-group>
            <article-title>The clinical features of cataplexy: a questionnaire study in narcolepsy patients with and without hypocretin-1 deficiency.</article-title>
            <source>Sleep Med</source>
            <year>2011</year>
            <month>Jan</month>
            <volume>12</volume>
            <issue>1</issue>
            <fpage>12</fpage>
            <page-range>12-8</page-range>
            <pub-id pub-id-type="pmid">21145280</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19004.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Burgess</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Scammell</surname>
                <given-names>TE</given-names>
              </name>
            </person-group>
            <article-title>Narcolepsy: neural mechanisms of sleepiness and cataplexy.</article-title>
            <source>J Neurosci</source>
            <year>2012</year>
            <month>Sep</month>
            <day>05</day>
            <volume>32</volume>
            <issue>36</issue>
            <fpage>12305</fpage>
            <page-range>12305-11</page-range>
            <pub-id pub-id-type="pmid">22956821</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19004.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pizza</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Antelmi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Vandi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Meletti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Erro</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Baumann</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Bhatia</surname>
                <given-names>KP</given-names>
              </name>
              <name>
                <surname>Dauvilliers</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Edwards</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Iranzo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Overeem</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tinazzi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Liguori</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Plazzi</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>The distinguishing motor features of cataplexy: a study from video-recorded attacks.</article-title>
            <source>Sleep</source>
            <year>2018</year>
            <month>May</month>
            <day>01</day>
            <volume>41</volume>
            <issue>5</issue>
            <pub-id pub-id-type="pmid">29425380</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19004.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schneider</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Mignot</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and Management of Narcolepsy.</article-title>
            <source>Semin Neurol</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>37</volume>
            <issue>4</issue>
            <fpage>446</fpage>
            <page-range>446-460</page-range>
            <pub-id pub-id-type="pmid">28837992</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19004.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nishino</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Okuro</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Armodafinil for excessive daytime sleepiness.</article-title>
            <source>Drugs Today (Barc)</source>
            <year>2008</year>
            <month>Jun</month>
            <volume>44</volume>
            <issue>6</issue>
            <fpage>395</fpage>
            <page-range>395-414</page-range>
            <pub-id pub-id-type="pmid">18596995</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19004.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barateau</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Dauvilliers</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Recent advances in treatment for narcolepsy.</article-title>
            <source>Ther Adv Neurol Disord</source>
            <year>2019</year>
            <volume>12</volume>
            <fpage>1756286419875622</fpage>
            <pub-id pub-id-type="pmid">31632459</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19004.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dauvilliers</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Barateau</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Narcolepsy and Other Central Hypersomnias.</article-title>
            <source>Continuum (Minneap Minn)</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>23</volume>
            <issue>4, Sleep Neurology</issue>
            <fpage>989</fpage>
            <page-range>989-1004</page-range>
            <pub-id pub-id-type="pmid">28777172</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19004.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kerr</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>McGuffie</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Wilkie</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Tricyclic antidepressant overdose: a review.</article-title>
            <source>Emerg Med J</source>
            <year>2001</year>
            <month>Jul</month>
            <volume>18</volume>
            <issue>4</issue>
            <fpage>236</fpage>
            <page-range>236-41</page-range>
            <pub-id pub-id-type="pmid">11435353</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19004.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bartlett</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Drug-Induced Serotonin Syndrome.</article-title>
            <source>Crit Care Nurse</source>
            <year>2017</year>
            <month>Feb</month>
            <volume>37</volume>
            <issue>1</issue>
            <fpage>49</fpage>
            <page-range>49-54</page-range>
            <pub-id pub-id-type="pmid">28148614</pub-id>
          </element-citation>
        </ref>
        <ref id="article-19004.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Matos</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Gaig</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Santamaria</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Iranzo</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Cataplexy causing subdural hematomas.</article-title>
            <source>Sleep Med</source>
            <year>2017</year>
            <month>Feb</month>
            <volume>30</volume>
            <fpage>15</fpage>
            <page-range>15-16</page-range>
            <pub-id pub-id-type="pmid">28215239</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
